司帕生坦的用法用量

Sparsentan is a drug used to treat specific kidney diseases. This article will elaborate on the recommended dosage, administration method, side effects and medication for special groups to help patients and medical workers use the drug rationally to achieve the best therapeutic effect and reduce adverse reactions.

Usage and Dosage of Sparsentan

Correct use requires strictly following the recommended dosage regimen and administration method, and must be administered under the guidance of a doctor.

Recommended dose

The initial dose of sparsentan is 200 mg orally once daily. After 14 days of treatment, if the patient tolerates it well, the dose can be increased to the recommended dose of 400 mg once daily. If treatment needs to be restarted after interruption for any reason, it should be started again at 200 mg once a day and adjusted to 400 mg once a day after 14 days. This dose escalation helps reduce initial adverse effects.

Dosage Mode

Patients should swallow the tablet whole with an appropriate amount of water before breakfast or dinner, and maintain the regularity of taking it before the same meal every day. If you miss a dose, you should take the normal dose at the next regular time. Do not take a missed dose or double the dose. This method of administration helps maintain stable blood drug concentrations.

Dose adjustment

For patients who experience significant adverse reactions, it may be necessary to temporarily reduce the dose or interrupt treatment. This drug should be avoided in patients with severe hepatic impairment, and dosage adjustments may be required in patients with mild to moderate hepatic impairment. When used in combination with other drugs, the impact of possible interactions on dosage should also be considered.

Sparsentan’s side effects

Understanding the possible side effects of Sparsentan can help patients identify abnormal reactions in time and take appropriate measures.

Common adverse reactions

Most patients may experience minor reactions such as peripheral edema, dizziness, and fatigue. These symptoms usually appear early in the treatment and may gradually lessen as treatment continues. If symptoms persist or worsen, adjustment of the medication regimen should be considered.

Serious adverse reactions

A small number of patients may experience serious reactions such as abnormal liver function, severe hypotension or hyperkalemia. These conditions require immediate medical attention and, if necessary, permanent discontinuation of the medication. Regular monitoring of liver function, blood pressure, and serum potassium levels is critical for early detection of these adverse effects.

Special Precautions

Sparsentan is absolutely contraindicated in pregnant women because of its clear risk of teratogenesis. Women of childbearing age must take reliable contraceptive measures during medication. Elderly patients and those with renal insufficiency should use this medication with caution and may require more frequent monitoring and dose adjustments.

Sparsentan medication for special populations

Different populations have different metabolisms and reactions to sparsentan, and individualized medication plans are required.

Patients with hepatic impairment

Patients with mild liver impairment may need to reduce the dose, and patients with moderate to severe liver impairment should avoid using this drug. Liver function indicators need to be monitored regularly during medication. If abnormalities occur, seek medical attention promptly.

Patients with renal insufficiency

Patients with mild to moderate renal insufficiency usually do not need to adjust the dose, but changes in renal function need to be closely monitored. Patients with severe renal insufficiency should use medication with caution and may need to reduce the dose or extend the dosing interval.

Drug use in elderly patients

Elderly patients over 65 years old may have increased sensitivity to drugs. The initial dose should be started at a low dose and slowly titrated to the target dose. At the same time, special attention should be paid to monitoring changes in blood pressure and renal function.

Pediatric Medication

Currently, the safety and effectiveness of sparsentan in children under 18 years of age have not been established, and its use in this population is not recommended. Pediatric patients should choose other proven treatment options.